Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program

Dubinsky MC, Magro F, Steinwurz F, Hudesman DP, Kinnucan JA, Ungaro RC, Neurath M, Kulisek N, Paulissen J, Su C, De Leon DP, Regueiro M (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Inflammatory Bowel Diseases Wiley

DOI: 10.1093/ibd/izac061

Abstract

Lay Summary Early decreases in partial Mayo score and C-reactive protein were found to be associated with achieving efficacy outcomes following tofacitinib 10 mg twice daily induction therapy in the ulcerative colitis clinical program.

Authors with CRIS profile

Markus Neurath Lehrstuhl für Innere Medizin I

Involved external institutions

Mayo Clinic

United States (USA) (US) Icahn School of Medicine at Mount Sinai

United States (USA) (US) Pfizer, Inc.

United States (USA) (US) Cleveland Clinic

United States (USA) (US) Universidade do Porto

Portugal (PT) Hospital Israelita Albert Einstein

Brazil (BR) New York University (NYU)

United States (USA) (US)

How to cite

APA:

Dubinsky, M.C., Magro, F., Steinwurz, F., Hudesman, D.P., Kinnucan, J.A., Ungaro, R.C.,... Regueiro, M. (2022). Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac061

MLA:

Dubinsky, Marla C., et al. "Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program." Inflammatory Bowel Diseases (2022).

BibTeX: Download